Literature DB >> 18922577

The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.

Deok-Hwan Yang1, Jung-Sun Park, Chun-Ji Jin, Hyun-Kyu Kang, Jong-Hee Nam, Joon-Haeng Rhee, Yeo-Kyeoung Kim, Sang-Young Chung, So-Jin-Na Choi, Hyeoung-Joon Kim, Ik-Joo Chung, Je-Jung Lee.   

Abstract

We investigated whether dendritic cells (DCs) from multiple myeloma (MM) patients were affected by loading tumor antigens and whether the defective DC function associated with MM could be overcome by the neutralization of VEGF. MM-specific DCs were generated by loading tumor lysates from myeloma cells at diagnosis or relapsed/progressive state, respectively. DCs loaded with tumor lysates showed lower phenotypic maturation, less T cell stimulatory capacity, less cytotoxic T lymphocyte activities, and highly abnormal cytokine secretions of IL-6 and IL-12, compared to myeloma lysate-unloaded DCs. The levels of VEGF, phospho-STAT3 and phospho-ERK1/2 in DCs were significantly higher with loading myeloma lysates. After the neutralization of VEGF activity, the DC function, signal transduction and cytokine production returned to normal. The defective function of DC in patients with MM is significantly affected by loading tumor antigens, correlating with abnormal STAT3 and the NF-kappaB signaling pathway, and neutralization of VEGF can overcome this DC dysfunction through the elimination of abnormal signal transduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922577     DOI: 10.1016/j.leukres.2008.09.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  24 in total

Review 1.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Authors:  Jae Hoon Lee; Dong Soon Lee; Je Jung Lee; Yoon Hwan Chang; Jong Youl Jin; Deog-Yeon Jo; Soo Mee Bang; Hyo Jung Kim; Jin Seok Kim; Kihyun Kim; Hyeon Seok Eom; Chang Ki Min; Sung Soo Yoon; Sun Hee Kim; Cheolwon Suh; Kyung Sam Cho
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

3.  Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro.

Authors:  Lihong Chen; Minglian Qiu; Wubing He; Aimin Huang; Jingfeng Liu
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

Review 4.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

Review 5.  STAT3: a target to enhance antitumor immune response.

Authors:  Heehyoung Lee; Sumanta Kumar Pal; Karen Reckamp; Robert A Figlin; Hua Yu
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

6.  Immune effects of bevacizumab: killing two birds with one stone.

Authors:  Yasir Y Elamin; Shereen Rafee; Sinead Toomey; Bryan T Hennessy
Journal:  Cancer Microenviron       Date:  2014-10-18

7.  Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate.

Authors:  Ke Pan; Jing-jing Zhao; Hui Wang; Jian-jun Li; Xiao-ting Liang; Jian-cong Sun; Yi-bing Chen; Hai-qing Ma; Qing Liu; Jian-chuan Xia
Journal:  Int J Biol Sci       Date:  2010-10-13       Impact factor: 6.580

8.  Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.

Authors:  Paul J Neeson; Andy K Hsu; Yin R Chen; Heloise M Halse; Joanna Loh; Reece Cordy; Kate Fielding; Joanne Davis; Josh Noske; Alex J Davenport; Camilla A Lindqvist-Gigg; Robin Humphreys; Tsin Tai; H Miles Prince; Joseph A Trapani; Mark J Smyth; David S Ritchie
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

Review 9.  Checkpoint modulation in melanoma: an update on ipilimumab and future directions.

Authors:  David B Page; Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 10.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.